CLINICAL & TRANSLATIONAL ONCOLOGY, vol.13, no.11, pp.826-830, 2011 (SCI-Expanded)
The identification of novel prognostic markers may help to better assess survival probability in different subgroups of patients with non-small-cell lung cancer (NSCLC) and to tailor treatment according to the molecular profile of the tumour.